CO2022007507A2 - Uso de reboxetina para tratar los trastornos del sistema nervioso - Google Patents
Uso de reboxetina para tratar los trastornos del sistema nerviosoInfo
- Publication number
- CO2022007507A2 CO2022007507A2 CONC2022/0007507A CO2022007507A CO2022007507A2 CO 2022007507 A2 CO2022007507 A2 CO 2022007507A2 CO 2022007507 A CO2022007507 A CO 2022007507A CO 2022007507 A2 CO2022007507 A2 CO 2022007507A2
- Authority
- CO
- Colombia
- Prior art keywords
- reboxetine
- nervous system
- treat disorders
- esreboxetine
- cataplexy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962943077P | 2019-12-03 | 2019-12-03 | |
US201962946295P | 2019-12-10 | 2019-12-10 | |
US16/740,329 US20200147093A1 (en) | 2018-10-15 | 2020-01-10 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,411 US20200147096A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,410 US20200147095A1 (en) | 2018-10-15 | 2020-01-11 | Use of esreboxetine to treat nervous system disorders such as fibromyalgia |
US16/740,409 US11351175B2 (en) | 2018-10-15 | 2020-01-11 | Use of reboxetine to treat narcolepsy |
PCT/US2020/062560 WO2021113163A1 (en) | 2019-12-03 | 2020-11-30 | Use of reboxetine to treat nervous system disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2022007507A2 true CO2022007507A2 (es) | 2022-06-21 |
Family
ID=81851750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2022/0007507A CO2022007507A2 (es) | 2019-12-03 | 2022-05-31 | Uso de reboxetina para tratar los trastornos del sistema nervioso |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP4069244A4 (ko) |
JP (1) | JP2023504685A (ko) |
KR (1) | KR20220108122A (ko) |
CN (1) | CN114746097A (ko) |
AU (1) | AU2020395082A1 (ko) |
BR (1) | BR112022010677A2 (ko) |
CA (1) | CA3163505A1 (ko) |
CO (1) | CO2022007507A2 (ko) |
CR (1) | CR20220247A (ko) |
IL (1) | IL293536A (ko) |
MX (1) | MX2022006630A (ko) |
PE (1) | PE20230181A1 (ko) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL197985B1 (pl) * | 1999-07-01 | 2008-05-30 | Upjohn Co | Zastosowanie optycznie czystej (S,S)-reboksetyny lub jej dopuszczalnej farmaceutycznie soli do wytwarzania leku |
PT1459750E (pt) * | 1999-07-01 | 2005-08-31 | Pharmacia & Upjohn Co Llc | (s,s)- reboxetina para tratar a fibromialgia ou outras perturbacoes somatoformes |
CA2686723A1 (en) * | 2007-05-07 | 2008-11-13 | Chelsea Therapeutics, Inc. | Droxidopa and pharmaceutical composition thereof for the treatment of mood disorders, sleep disorders, or attention deficit disorders |
TWI684450B (zh) * | 2013-03-13 | 2020-02-11 | 南韓商愛思開生物製藥股份有限公司 | 猝倒症之治療 |
-
2020
- 2020-11-30 CR CR20220247A patent/CR20220247A/es unknown
- 2020-11-30 AU AU2020395082A patent/AU2020395082A1/en not_active Abandoned
- 2020-11-30 BR BR112022010677A patent/BR112022010677A2/pt unknown
- 2020-11-30 EP EP20895126.9A patent/EP4069244A4/en active Pending
- 2020-11-30 CA CA3163505A patent/CA3163505A1/en active Pending
- 2020-11-30 IL IL293536A patent/IL293536A/en unknown
- 2020-11-30 CN CN202080083484.4A patent/CN114746097A/zh active Pending
- 2020-11-30 JP JP2022533248A patent/JP2023504685A/ja active Pending
- 2020-11-30 MX MX2022006630A patent/MX2022006630A/es unknown
- 2020-11-30 KR KR1020227022167A patent/KR20220108122A/ko unknown
- 2020-11-30 PE PE2022000980A patent/PE20230181A1/es unknown
-
2022
- 2022-05-31 CO CONC2022/0007507A patent/CO2022007507A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20230181A1 (es) | 2023-02-01 |
EP4069244A1 (en) | 2022-10-12 |
AU2020395082A1 (en) | 2022-06-09 |
CR20220247A (es) | 2022-08-18 |
EP4069244A4 (en) | 2023-12-20 |
CN114746097A (zh) | 2022-07-12 |
KR20220108122A (ko) | 2022-08-02 |
IL293536A (en) | 2022-08-01 |
JP2023504685A (ja) | 2023-02-06 |
BR112022010677A2 (pt) | 2022-08-16 |
MX2022006630A (es) | 2022-06-24 |
CA3163505A1 (en) | 2021-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2018013747A2 (es) | Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos | |
CL2019000510A1 (es) | Adenovirus armado con un activador de células t biespecífico (bite). | |
CL2022001743A1 (es) | Dosis de gamma-hidroxibutirato (ghb) | |
ECSP22023220A (es) | Derivados de indol mono o disustituidos como inhibidores de la replicación viral del dengue | |
CO2019000938A2 (es) | Moduladores nmda espiro-lactam y métodos de uso de los mismos | |
UY37271A (es) | Composiciones nasales de cannabinoides | |
CO2019000944A2 (es) | Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos | |
GT201700246A (es) | Métodos y kits para tratar la depresión | |
CO2019000945A2 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
CL2021000924A1 (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
AR107871A1 (es) | Combinaciones de inhibidores de lsd1 para su uso en el tratamiento de tumores sólidos | |
CL2019000247A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
CL2019000246A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos. | |
CO2021015793A2 (es) | Métodos para tratar o prevenir el asma mediante la administración un antagonista de il-33 | |
CL2019002218A1 (es) | Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular. | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
CO2022014499A2 (es) | Moduladores de nlrp3 | |
CO2020007601A2 (es) | Cepa vacunal de brucella modificada para el tratamiento de brucelosis | |
MX2020004513A (es) | Cocristales, composiciones farmacéuticas de los mismos y métodos de tratamiento que los implican. | |
BR112019004540A2 (pt) | método para tratar demência em um paciente, composição farmacêutica, método para tratar demência em um paciente, método para reduzir a probabilidade de desenvolver demência em um paciente, composição para uso no tratamento de demência em um paciente, composição e composição para uso na redução da probabilidade de desenvolver demência em um paciente submetido a uma terapia longa de um fármaco não-esteroide anti-inflamatório ou aspirina | |
CO2022007507A2 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
CL2022001476A1 (es) | Uso de reboxetina para tratar los trastornos del sistema nervioso | |
ECSP22092205A (es) | Composición farmacéutica acuosa de levilimab y su uso | |
AR122344A1 (es) | Uso de reboxetina para tratar desórdenes del sistema nervioso |